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Abstract
KML001 is sodium metaarsenite, and has shown cytotoxic activity in human tumor cell lines. The anti-cancer mechanism of
KML001 involves cancer cell destruction due to DNA damage at the telomeres of cancer cell chromosomes. In this study, we
assessed the vascular disrupting properties of KML001 and investigated whether KML001 as VDA is able to increase anti-
tumor activity in irinotecan combined treatment. We used a murine model of the CT26 colon carcinoma cell line. CT26
isograft mice treated intraperitoneally with 10 mg/kg KML001 displayed extensive central necrosis of tumor by 24 h. The
vascular disrupting effects of KML001 were assessed by dynamic contrast enhanced magnetic resonance imaging.
Gadopentetic acid-diethylene triaminepentaacetic acid contrast enhancement was markedly decreased in KML001-treated
mice one day after treatment, whereas persistently high signal enhancement was observed in mice injected with saline.
Rate constant Kep value representing capillary permeability was significantly decreased (p,0.05) in mice treated with
KML001. Cytoskeletal changes of human umbilical vein endothelial cells (HUVECs) treated with 10 uM KML001 were
assessed by immune blotting and confocal imaging. KML001 degraded tubulin protein in HUVECs, which may be related to
vascular disrupting properties of KML001. Finally, in the mouse CT26 isograft model, KML001 combined with irinotecan
significantly delayed tumor growth as compared to control and irinotecan alone. These results suggest that KML001 is a
novel vascular disrupting agent, which exhibits significant vascular shut-down activity and enhances anti-tumor activity in
combination with chemotherapy. These data further suggest an avenue for effective combination therapy in treating solid
tumors.
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Introduction
KML001 (sodium metaarsenite) is an orally available arsenic
compound that has entered phase II clinical trials in solid tumors.
This agent has shown cytotoxic activity in human tumor cell lines.
Significant anti-cancer effects and stabilization have been reported
in clinical studies with prostate cancer patients. KML001 was
reported to be able to destroy and control cancer cells by causing
DNA damage only at the telomeres of chromosomes in cancer
cells [1]. However, such clinical results cannot be fully explained
only with the aforementioned mechanisms because the agent
shows anti-cancer effects in patients with a variety of cancers and is
less toxic. Accordingly, information is needed concerning the main
molecular biological mechanisms that may explain the anti-cancer
effects of KML001.
Anti-angiogenic drugs applied in clinical trials as treatments for
solid tumors including lung cancer and colorectal cancer exert
their anti-cancer effects by normalizing the pathological abnor-
malities of tumor vessels and controlling neovascularization [2].
Among these drugs, vascular disrupting agents (VDAs) are a recent
addition and represent a novel therapeutic approach. A VDA has
different mechanism from existing anti-vascular endothelial
growth factor (VEGF) agents such as bevacizumab, sunitinib
and sorafenib. Combined with tubulin in the endothelial cells of
the blood vessels, VDAs inhibit blood flow to tumors and cause
tumor necrosis within a few hours after administration [3].
Because VDAs rarely affect normal vessels, they do not cause
malfunction of liver, kidneys, brain or any other normal organs.
Therefore, VDAs are regarded as safe and minimally toxic [4].
The selectivity of VDAs for tumor vessels is thought to be a
consequence of the vessels’ pathological abnormalities. VDAs bind
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Figure 1. Gross morphological and histopathological changes. (A) Observation on necrosis in tumor after treatment of KML001 in CT26
isograft model. (B) Tumors were excised from CT26 isografts treated with PBS or KML001. (C–E) Histological analysis of tumor tissues (C, x100 and D,
x400) and normal tissues (E) treated with KML001.
doi:10.1371/journal.pone.0053900.g001
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to the tubulin of the endothelial cells in the tumor vessels and
cause cell-to-cell junctions or cytoskeleton disruption. They
transform the endothelial cell shape, increase protein permeability
in the blood vessels, and cause vascular occlusion by vascular
constriction arising from increased interstitial pressure, increased
blood viscosity, hemo-concentration and serotonin secretion [4].
This causes tumor hypoxia and necrosis. VDAs under develop-
ment or under clinical trials include CA4DP, AVE8062A and
OXi4503 [5]. In combination with the standard anti-cancer
therapy in Phase II trials in patients with advanced lung cancer,
ASA404 has extended survival [6].
Since arsenic was first shown to have clinical effects in patients
with acute promyelocytic leukemia (APL) in China in the 1970s,
more than 80% of patients treated with arsenic trioxide (ATO)
have displayed beneficial clinical effects without acute toxicity
[7,8]. The biological activity of ATO reported so far explains the
anti-cancer effects with a variety of mechanisms including anti-
tubulin effect, differentiation induction, apoptosis, anti-prolifera-
tive activity and angiogenesis inhibition. [9–11]. Acute tumor
vascular shutdown and massive tumor necrosis similar to those
observed in VDAs was documented when ATO was administered
in a murine tumor model [12]. Given that KML001 is a derivative
of arsenic trioxide, it is very possible that the anti-cancer effect of
the agent might result from tumor vascular disruption.
Here, we report the vascular disrupting effects of KML001 in
CT26 isograft mice. The compound did not affect blood supply to
normal organs including liver and kidneys, and so had limited
effects on tumor vessels. Use of human umbilical vein endothelial
cells (HUVECs) supported the view that KML001’s vascular
disrupting effect resulted from the morphologic change of
endothelial cells by cytoskeleton-associated protein degradation
of tubulin. Our results indicate that KML001 is a new VDA,
which, in combination with irinotecan, enhances anti-tumor
activity in CT26 isograft mice.
Materials and Methods
Cell Culture and Reagents
HUVECs were purchased from ATCC (Manassas, VA, USA)
and were maintained in Ham’s Kaighn’s Modification F12 (F12K;
Invitrogen, Carlsbad, CA, USA) supplemented with 2 mM L-
Glutamine (Invitrogen) and 0.1 mg/ml heparin sodium salt from
porcine intestinal mucosa (Sigma-Aldrich, St. Louis, MO, USA),
0.05 mg/ml Endothelial Cell Growth Supplement (ECGS; BD,
Franklin Lakes, NJ, USA) and 10% fetal bovine serum (FBS;
Invitrogen). The medium was prepared fresh every 2 weeks. The
murine CT26 colon carcinoma cell line (ATCC) was routinely
maintained in RPMI 1640 medium supplemented with 10% FBS.
KML001 (sodium metaarsenite, formerly known as Kominox) was
obtained from Komipharm International (Seoul, Korea) and
50 mmol/l stock solutions were prepared in phosphate buffered
saline (PBS). Aliquots of the stock were stored at220uC. The stock
solutions were stable for over 1 year. Working concentrations were
freshly prepared daily by diluting the stock with complete RPMI
1640. Irinotecan (Sigma-Aldrich) was prepared at a 0.1 M
concentration in PBS.
Animal and Tumor Model
All research was governed by the principles of the Guide for the
Care and Use of Laboratory Animals and approved by the
University of Ulsan Animal Care and Use Committee. Female
Balb/c mice (6–8 weeks of age) were obtained from ORIENTBIO
(Seoul, Korea) and were maintained under specific pathogen-free
conditions.
Histological Analysis
CT26 cells were harvested from monoconfluent monolayer cell
cultures in 16PBS and 26106 cells in a total volume of 100 ml and
were injected subcutaneously. When the tumor size became 3 mm
in diameter, the control group was injected with PBS solution with
5% dextrose, while the experimental group was intraperitoneally
injected with 100 ml of KML001 at a concentration of 10 mg/kg
with 5% dextrose. At 8, 24 and 48 hours after injection, the liver,
spleen and tumor tissues were acquired and put into a 37%
solution of formaldehyde for 24 hours. The tissues were inserted
into paraffin and sectioned at a thickness of 4 mm using a
microtome (SLEE MAINZ GmbH, Germany). The sections were
placed on slides and stained with Mayer’s hematoxylin and eosin
Y (both from Sigma-Aldrich). Images were observed using a model
BX50 inverted microscope (Olympus, Tokyo, Japan).
Tumor Perfusion Measurement
Magnetic resonance imaging (MRI) examination was performed
8 and 9 days after subcutaneous inoculation of 26106 CT26 cells.
Balb/C mice were anesthetized by 2% isoflurane mixed with
100% 1 l/min O2 via a nose cone. A catheter was inserted into the
tail vein for injection of 281 mg/kg gadopentetic acid-diethylene
triaminepentaacetic acid (Gd-DTPA; Magnevist, Schering, Ger-
many). T2-weighted turbo spin echo images were acquired on
coronal planes using the following parameters: TE= 60 ms,
TR=3200 ms, field of view (FOV) = 50 mm, RFOV
(%) = 69.94%, matrix scan= 224, reconstruction= 512, 0.5 mm
thick slices, 14 slices, and acquisition time= 8 min 38 s. T1-
weighted spin-echo images were acquired on coronal planes as
pre- and post-dynamic contrast enhanced MRI scan using the
following parameters: TE= 7.9 ms, TR=427 ms, field of view
(FOV) = 50 mm, RFOV (%) = 70%, matrix scan= 128, recon-
struction = 256, 1 mm thick slices, 11 slices, and acquisition
time= 2 min 8 s. For dynamic contrast enhanced (DCE)-MRI
scan, Gd-DTPA (Magnevist) was administrated at a dose of
281 mg/kg via tail-vein injection. DCE-MRI was performed using
a perfusion-weighted spin echo sequence using the following
acquisition parameters: FOV (mm)= 50635, RFOV (%)= 71,
matrix scan= 112, reconstruction = 224, TR/TE (ms) = 12/4.0,
slice number= 11, dynamic scans = 60, 1 mm slice thickness with
a total acquisition time of 2 min 6 s.
MRI images were downloaded from a Philips MRI scanner in
the Philips PARREC format, and the images were transferred to a
processing workstation connected to the research network. The
programming languages used were IDL 8.1 (ITT, Boulder, CO,
USA). The data was analyzed by the BRIX model method.
Cytotoxicity Assay
The cytotoxicity assay was used to determine drug-mediated
cytotoxicity by using (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) reagent
of the Cell Titer 96 Aqueous One Solution (Promega, Madison,
WI, USA) with absorption measured at 490 nm, as described
previously [16]. Briefly, the assay entailed seeding HUVECs at
0.56105 cells per well for 24 h at 37uC and 5% CO2. After
addition of the drugs at the indicated concentrations, the cells were
incubated for either 24 or 48 h. Twenty microliters of the MTS
solution was added to each well and incubated at 37uC for 4 h.
Thereafter, absorbance values (A) for each well were measured
using a microplate spectrophotometer (Bio-Tek, Winooski, VT,
USA). The percentage of viable cells was calculated using the
background-corrected absorbance using the following calculation:
% cytotoxicity = (1–A of experimental well/A of positive control
well)6 100.
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Figure 2. Quantitative analysis of the DCE-MRI parameter in the CT26 isograft model. (A) T1-weighted gadolinium contrast enhanced MRI
of pre-treatment and 24 h post-treatment. Arrows indicates enhancing tumors at the proximal hind leg of the mice. (B) The quantitative parameter
Kep values of each animal treated with KML001 and saline. (C) Changes in the mean values of Kep measured pre and 24 h post-treatment. (*indicate
P,0.05).
doi:10.1371/journal.pone.0053900.g002
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Flow Cytometry
HUVECs (26106 cells) were treated with each drug at the
indicated concentration for 24 h. Cells were washed with PBS by
spinning at 1,000 rpm for five min at 4uC and fixed with 1 ml of
ice-cold 95% ethanol drop-wise while vortexing. The fixed cells
were incubated on ice for at least 30 min and then washed as
described above. The pellets were resuspended in 1 ml PBS and
100 ml of a 1 mg/ml propidium iodide (PI) stock was added for
5–10 min at room temperature. Flow cytometry was performed
using a FACSCalibur flow cytometer and Cell Quest software
(BD Biosciences).
Immunoblots
HUVECs grown to 70%–80% confluence in a F25 culture flask
were harvested after drug treatment in 100 ml/well of protein lysis
buffer containing 50 mM Tris, pH 7.5, 150 mM NaCl, 1% NP-
40, 0.5% sodium deoxychloate, 0.1% sodium dodecyl sulfate
(SDS), and protease inhibitor (protease inhibitor cocktail tablets;
Roche, Basel Switzerland) plus 200 units/ml aprotinin (Sigma-
Aldrich) and 10 mmol/l trichostatin A (Cayman Chemical, Ann
Arbor, MI, USA). Protein concentrations were determined using a
commercial protein assay reagent (Bio-Rad, Hercules, CA, USA)
and 3 mg protein were loaded into each well and resolved using
10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE). After
protein transfer onto nitrocellulose, blots were blocked using 5%
milk and each blot was probed with anti-glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) (Santa Cruz Biotechnology)
as an internal control. Other primary antibodies used were anti-a-
tubulin (Santa Cruz Biotechnology) and the membrane was
reacted with goat anti-mouse lgG secondary antibody (Santa Cruz
Biotechnology) conjugated to horseradish peroxidase (HRP) and
exposed to light with Molecular Imager ChemiDoc XRS (Bio-
Rad) using Immun-StarTM and quantified by Quantity One Image
analyzer (Bio-Rad).
Reverse Transcription-polymerase Chain Reaction (RT-
PCR)
HUVECs (ATCC) were cultivated in F25 culture flasks
containing F-12K medium (Sigma-Aldrich) supplemented with
10% FBS and ECGS (Sigma-Aldrich). After cultivation for 24 h,
the cells were treated with 5 uM, 10 uM and 20 uM KML001. At
6 and 48 h after the treatment, the cells were collected. Total
RNA was extracted using Trizol (Invitrogen) from the collected
cells using alcohol precipitation. One microgram of total RNA was
reverse transcribed. PCR was performed on cDNA template using
Taq polymerase (Bioneer, Seoul, Korea) and the following
primers: a-tubulin (sense: 59-ATT GTG CCT TCA TGG TAG
AC-39, antisense: 59-TTC TGT CAG GTC AAC ATT CA-39), b-
tubulin (sense: 59-AAC GAC CTC GTC TCT GAG TA-39,
antisense: 59-AAT TCT GAG GGA GAG GAA AG-39) and
GAPDH (sense: 59-ACC ACT TTG TCA AGC TCA TT-39,
antisense: 59-AGT GAG GGT CTC TCT CTT CC-39). The
PCR product was confirmed by 1.5% agarose gel electrophoresis.
Immunofluorescene and Confocal Microscopy
HUVECs were cultured on the confocal dish (SPL, Seoul,
Korea) with F-12K (Sigma-Aldrich) medium containing 10% FBS
and endothelial cell growth supplement (ECGS, E2759; Sigma-
Aldrich). After cultivation for 24 h, the cells were treated with
KML001 at concentrations of 1 uM, 5 uM, or 10 uM. At 24 h
and 48 h after the treatment, the cells were fixed with 3.7%
paraformaldehyde at the room temperature for 10 min. After
being washed with PBS solution three times, the cells were treated
with 0.15% Triton X-100 for 15 min and washed three times with
PBS. After being blocked with 2% bovine serum albumin (BSA,
Sigma-Aldrich) at room temperature for 60 min, the cells were
also washed three times with PBS. Monoclonal antibody against a-
tubulin (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was
used to react with cell tubulin at room temperature for 1 h and the
cells were washed three times with PBS. They were reacted with
rat anti-mouse IgG1 secondary antibody (BD Bioscience, Franklin
Lakes, NJ, USA) conjugated to fluorescein isothiocynate (FITC).
After being washed three times with PBS, the cells were analyzed
using a model FV500 confocal laser scanning microscope
(Olympus, Tokyo, Japan).
Figure 3. Analysis of apoptosis and cytotoxicity of HUVECs by KML001. (A) Effects of KML001 on the cytotoxicity of HUVECs Cell cytotoxicity
was assessed by the MTT assay. Representative of three independent experiments. Columns, mean; bars, SD. (*indicate P,0.05 compare to PBS) (B)
Induction of apoptosis in HUVECs by KML001. (*indicate P,0.05 compare to PBS).
doi:10.1371/journal.pone.0053900.g003
Figure 4. KML001 induces depolymerization of microtubules in
HUVECs. HUVECs were treated with KML001, or no drug as the control,
for 24 h at the indicated concentrations. (A) Cell lysates were separated
into polymerized (P) or soluble (S) fractions by centrifugation 2000 rpm
at 22uC for 30 min. Equal volumes were separated by SDS-PAGE and
evaluated by Immunoblot probed with anti-a-tubulin. (B) Densitometric
analysis showing relative protein level of each fraction and normalized
with respect to GAPDH are shown. Representative of three independent
experiments. Columns, mean; bars, SD. (*indicate P,0.05 compare to
0 mM).
doi:10.1371/journal.pone.0053900.g004
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Anti-tumor Activity
Anti-tumor effects of irinotecan or KML001 were evaluated in
the mouse CT26 isograft model. Female BALB/c mice weighing
approximately 20 g were inoculated by subcutaneous injection
with 26106 of CT26 cells per mouse. When tumors became 3 mm
in diameter, the control group was injected weekly with PBS
containing 5% dextrose. The experimental groups were divided
into a group injected with 100 ml of irinotecan (15 mg/kg/week
with 5% dextrose, for 4 weeks) and the other group injected with
100 ml of both KML001 (10 mg/kg/week with 5% dextrose, for 4
weeks). Mice were monitored for toxicity by body weight
measurements and tumor growth was measured once every 2 days
using calipers throughout the experimental period. Tumor
volumes were calculated based on the following formula: tumor
volume= (length6width2)6p/6.
In a combination experiment, when the tumor size reached
3 mm in diameter, mice were randomized into different treatment
groups: irinotecan alone (15 mg/kg/week with 5% dextrose),
irinotecan (15 mg/kg) combined with KML001 (10 mg/kg), and
vehicle control (16PBS with 5% dextrose). All experiment groups
were treated weekly for 4 weeks.
Statistical Analysis
The results obtained from at least three independent experi-
ments were expressed as mean 6 standard deviation. One-way
ANOVA test were used to determine the differences between
control and treatment groups. P,0.001 was considered to be
statistically significant. All data were analyzed using GraphPad
software.
Results
Gross Morphological and Histopathological Changes
Fig. 1A illustrates the gross tumor morphology before and after
a single injection ofKML001. While the discoloration of the tissues
of the mice injected without KML001 was not observed for a
certain period of time, the central part of tumors in the tissues of
the mice injected with KML001 became discolored at 24 h after
the injection of KML001. With time, the tumors became
discolored regardless of the injection of KML001. In case of
white mice injected with KML001, the tissues in the central part
became discolored by necrosis.
The sequential histopathological changes after drug treatment
are shown in Fig. 1B and 1C. In case of the tumor tissues of white
mice who did not receive KML001, the cell density remained
constant and the cells were distributed without any change in
shape. On the contrary, when the exposure time of KML001
increased, the scope of necrotic cell death in the tumor tissues of
mice injected with KML001 increased and necrotic cell death was
evident in the central part of the tumors. In liver, spleen and
kidney tissues, KML001-mediated ischemic damage was not
observed.
Quantitative Analysis of DCE-MRI
T1-weighted MRI revealed a difference between pre-treatment
and 24 h post-treatment Gd-DTPA contrast enhancement
(Fig. 2A). The degree of enhancement was significantly decreased
in the KML001 treated group as compared to the saline injection
group. Fig. 2B shows the decreasing of the quantitative parameter
Kep values of each animal treated with KML001 and saline. Kep
representing vascular leakage was significantly decreased in the
KML001 treatment group at 24 h after injection (Fig. 2C).
Analysis of Apoptosis and Cytotoxicity of HUVECs by
KML001
To assess the effect of KML001 on vascularization, we first
analyzed the effect on endothelial cells, which are important for
vascularization. Cytotoxicity was evident at 10 uM and was
induced more in proportion to time (Fig. 3A). In addition,
KML001 as an arsenic derivative is known to cause a variety of
physiologic effects. Fluorescence-activated cell sorting analysis
revealed that apoptosis increased depending on the concentration
of KML001, and was especially apparent with prolonged
treatment (Fig. 3B).
KML001 Induces Microtubule Depolymerization in
HUVECs
To investigate whether apoptosis was caused by a cytoskeletal
abnormality, which is important for cell division and cell
differentiation, the change in a-tubulin expression in the
cytoskeleton was identified by the division of tubulin into the
isolated form (soluble, S) and polymerized form (ppt, P). This
procedure and subsequent modifications have been widely used
and allow a quick and consistent assessment of the proportion of
tubulin polymer in cells under a variety of experimental
conditions. An increase in the S fraction served as an indicator
of destabilized tubulin. A higher concentration of KML001
Figure 5. KML001 promotes degradation of a- and b-tubulin in HUVECs. (A) Immunoblot of HUVECs treated with KML001 (0, 5, 10, 20, and
50 mM) for 24 h and 48 h. Blots were hybridized with a- and b-tubulin antibody. GAPDH was used as a loading control, (B) Densitometric analysis
showing relative protein level of a-tubulin and b-tubulin and normalized with respect to GAPDH are shown. Representative of three independent
experiments. Columns, mean; bars, SD. (*indicate P,0.05 compare to 0 mM). (C) Tubulin mRNA expression in HUVECs treated with KML001 (0, 5, 10,
and 20 mM) for 24 h and 48 h. (D) Analysis of change in microtubules by immunocytochemistry from HUVECs treated with KML001.
doi:10.1371/journal.pone.0053900.g005
Figure 6. KML001 alone treatment has a no inhibitory effect on
tumor in CT26 isograft models. Control group mice were injected
intraperitoneally with saline. Irinotecan group mice were injected with
15 mg/kg irinotecan. KML001 group was injected with 10 mg/kg
KML001. All experiment groups were administrated once weekly for 4
weeks. Black arrowheads indicate treatment. *P,0.0001 compared to
control.
doi:10.1371/journal.pone.0053900.g006
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reduced the protein level in both the supernatant liquid (isolated
tubulin) and the sediment (polymerized tubulin) (Fig. 4A and 4B).
The findings were consistent with the notion that KML001 not
only isolates the polymerized tubulin from the polymer but also
reduces the overall amount of tubulin by inducing the isolated
tubulin.
Change in Tubulin Protein in HUVECs Treated with
KML001
To check the change in the overall expression of tubulin, the
total amount of tubulin protein was identified by Western blotting.
A higher concentration of KML001 reduced the protein level on
a-tubulin and b-tubulin (Fig. 5A and 5B), supporting the idea that
KML001 drives the specific destruction of a-tubulin and b-tubulin
proteins.
To make it clear whether the change in tubulin protein resulted
from the cellular gene expression level through the aforemen-
tioned experiment or not, RT-PCR was performed. a-Tubulin
and b-tubulin mRNA levels were unchanged at 24 h and 48 h
after the treatment of KML001 at each concentration (Fig. 5C).
Because KML001 treatment resulted in the destabilization of
tubulin, we tested whether KML001 treatment affected the
cellular microtubule network. Cells treated with KML001
displayed a reduced total amount of microtubules, depending on
the KML001 concentration (Fig. 5D). These data supported the
suggestion that the quantitative change in the protein of a-tubulin
and b-tubulin from HUVECs was not caused by the change in the
expression of mRNA, but by the change in the protein level.
Anti-tumor Activity of KML001 in the CT26 Isograft Model
Because irinotecan (CPT-11) is a chemotherapeutic agent
widely used in colorectal cancer, small cell lung cancer and
several other solid tumors [13], we choose irinotecan as a
combination partner in this study. To evaluate the anti-tumor
effects of irinotecan alone or KML001 alone, CT26 isograft mice
were treated with KML001 (10 mg/kg) or irinotecan (15 mg/kg),
and tumor growth was compared with vehicle-treated control.
KML001 alone treatment did not delay the progression of tumor
growth, but irinotecan alone delayed progression of tumor growth
to day 26 (Fig. 6). This data suggested that KML001 alone
treatment has a no inhibitory effect on tumor in the CT26 isograft
model.
Irinotecan Combined with KML001 has an Additive
Inhibitory Effect in the CT26 Isograft Model
To evaluate the anti-tumor effects of irinotecan treatment alone
or in combination with KML001, we used four different sequences
of administration. The experimental groups were divided into one
group injected with 100 ml of irinotecan at the concentration of
15 mg/kg and a second group injected with 100 ml of KML001
(10 mg/kg in 5% dextrose) and irinotecan (15 mg/kg) at defined
times. Twenty four hours after being injected with irinotecan, mice
were injected with KML001 (Fig. 7A). At 24 h and 72 h after
being injected with irinotecan, mice were injected with KML001
(Fig. 7B). At 72 hours after being injected with irinotecan, mice
were injected with KML001 (Fig. 7C). All treatments were
administrated once weekly for 4 weeks. Compared to the
administration of only irinotecan, KML001+ irinotecan produced
a 2-fold increase in tumor inhibition.
In the CT26 isograft model, growth was inhibited with
irinotecan alone as compared to control (23.0%, 23.2%, and
25.0% in Fig. 7A, 7B, and 7C, respectively). However, mice
treated with KML001 + irinotecan showed a significantly tumor
Figure 7. Irinotecan combined with KML001 has an additive
inhibitory effect in CT26 isograft models. (A) At 24 h after being
injected with irinotecan (once weekly), injected with KML001 (once
weekly). (B) At 24 h and 72 h after being injected with irinotecan (once
weekly), injected with KML001 (twice weekly). (C) At 72 h after being
injected with irinotecan (once weekly), injected with KML001 (once
weekly) and all experiment groups were performed for 4 weeks. Black
(irinotecan) and white (KML001) arrowheads indicate treatment. *,
P,0.0001 compared to control. **, P,0.0001 compared to irinotecan.
doi:10.1371/journal.pone.0053900.g007
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growth delay as compared to control and irinotecan alone (45–
56%).
Discussion
VDAs have shown much promise pre-clinically as anti-cancer
therapeutics, and a small number are currently being investigated
in clinical trials. However, the failure of such agents to target the
peripheral tumor rim means that their efficacy as a single-agent
therapeutic strategy is in need of improvement [14]. One revised
strategy involves treatment in combination with standard chemo-
therapeutic agent that can destroy the remaining tumor cells.
There have been several pre-clinical studies that have demon-
strated improved efficacy [15]. This approach has recently been
reported as having some success in Phase II clinical trials using
combretastatin A4 phosphate in combination with carboplatin and
paclitaxel [16]. In this study, we demonstrate that KML001
induces a prompt and selective vascular shut down leading to
massive central necrosis in CT26 isograft model.
The biological response of tumors to VDA treatment is typically
characterized by early increases in vascular permeability followed
by vascular collapse and cessation of blood flow leading to
ischemia and tumor necrosis [17–19]. DCE-MRI is one of the
most widely used imaging methods for assessment of angiogenesis
in preclinical studies [20,21]. Several studies have highlighted the
usefulness of MRI in the assessment of tumor vascular response to
VDAs [22]. In this study, we also demonstrated the vascular effect
of KML001 using DCE-MRI. T1-weighted MRI revealed a
difference between pre-treatment and 24-h post-treatment Gd-
DTPA contrast enhancement. Degree of enhancement was
significantly decreased in the KML001 treated group compared
to the saline injection group. Kep representing vascular leakage
was significantly decreased in KML001 treatment group at 24 h
after injection.
First introduced into clinical oncology in the 1960s, microtubule
target agents (MTAs) are essential components in the therapy of
many cancers, including lymphoma as well as breast, ovarian,
lung, and head and neck cancers [23]. In cancer cells, the focus
has often been on their ability to interfere with mitosis, a thesis
developed with rapidly proliferating in vitro models that has never
been proven in patients [24]. Tubulin polymerization inhibitors
act primarily by disrupting the tubulin network of the endothelial
cell cytoskeleton, leading to shape changes and increased vascular
permeability. Our in vitro study results provide supportive
evidence of increased tumor vascular damage following
KML001 treatment. KML001 reduced the protein level on both
the supernatant liquid (isolated tubulin) and the sediment
(polymerized tubulin) by immunoblot using HUVECs and then
reduced the total amount of microtubules depending on concen-
tration, as shown by confocal imaging. These results support that
KML001 is a novel VDA.
Furthermore, we evaluated the anti-tumor efficacy of irinotecan
in combination with KML001. The sequence of administration
should be carefully designed to avoid an effect of one agent with
the other. Ideally, a combination of VDAs and cytotoxic agents is
expected to take advantage of the effect of the former on
endothelial cells and of the latter on tumor cells. The effects of
VDAs on the vasculature have obvious important implications in
the design of combination treatments with these agents, given their
possible interference with the distribution of the cytotoxic drug
[25–27]. In this respect, the sequence of administration can be
selected according to two main rationales: on the one hand, vessel
shutdown induced by the VDA given after the cytotoxic
compound would cause trapping of the already present cytotoxic
drug within the tumor, and, at the same time, would prevent the
possible VDA-induced impairment of drug distribution in the
tumor. So, in this study, we used the three different sequences of
administration. Interestingly, all of different sequences showed the
inhibitory effect of tumor growth more than the irinotecan alone
group. In the CT26 isograft model, tumor growth was inhibited
with irinotecan alone as compared to control (23.0%–25.0%).
However animals treated with irinotecan+KML001 showed
significant tumor growth delay as compared to control and
irinotecan alone (45%–56%).
This study demonstrates that KML001 is a novel VDA, which
exhibits significant vascular shut down activity in CT26 isograft
model and enhances antitumor activity in combination with
chemotherapy, and suggests a avenue for effective combination
therapy in treating solid tumors.
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